Antisense oligonucleotide (ASO) therapy has been approved by FDA for treatment of some populations of DMD, and is rationally designed to induce skipping of specific exons at the pre-mRNA level to restore the reading frame, producing truncated—yet functional—dystrophin [5, 7, 10–12]. Here, DMD is linked to Duchenne muscular dystrophy.